Pfizer Inc and King Pharmaceuticals Inc have signed an acquisition and merger agreement worth USD 3.6 B with King’s shares being valued at a 40 % premium. King’s pain management portfolio, Meridian auto- injector, and animal health care businesses would complement Pfizer’s existing business lines.